Below are the top 10 Pharmaceutical stocks with highest upside potential,
UPDATED TODAY before 4:30 AM ET, based on the difference between current price
and Wall Street analysts average target price. One Chinese company (CBP) is on
the list. Marina Biotech, Inc. (NASDAQ:MRNA) has the 1st highest upside
potential in this segment of the market. Its upside is 507.5%. Its consensus
target price is $3.25 based on the average of all estimates. Biostar
Pharmaceuticals, Inc. (NASDAQ:BSPM) has the 2nd highest upside potential in this
segment of the market. Its upside is 340.3%. Its consensus target price is $7.00
based on the average of all estimates. DARA BioSciences, Inc. (NASDAQ:DARA) has
the 3rd highest upside potential in this segment of the market. Its upside is
325.6%. Its consensus target price is $11.58 based on the average of all
estimates. Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) has the 4th highest
upside potential in this segment of the market. Its upside is 236.9%. Its
consensus target price is $4.75 based on the average of all estimates. China
Botanic Pharmaceutical Inc (AMEX:CBP) has the 5th highest upside potential in
this segment of the market. Its upside is 227.5%. Its consensus target price is
$4.88 based on the average of all estimates. CytRx Corporation (NASDAQ:CYTR) has
the 6th highest upside potential in this segment of the market. Its upside is
221.0%. Its consensus target price is $2.60 based on the average of all
estimates. Hemispherx BioPharma, Inc (AMEX:HEB) has the 7th highest upside
potential in this segment of the market. Its upside is 206.1%. Its consensus
target price is $1.50 based on the average of all estimates. AVANIR
Pharmaceuticals (NASDAQ:AVNR) has the 8th highest upside potential in this
segment of the market. Its upside is 194.8%. Its consensus target price is
$12.00 based on the average of all estimates. XOMA Limited (NASDAQ:XOMA) has the
9th highest upside potential in this segment of the market. Its upside is
188.5%. Its consensus target price is $8.80 based on the average of all
estimates. EpiCept Corporation (NASDAQ:EPCT) has the 10th highest upside
potential in this segment of the market. Its upside is 166.4%. Its consensus
target price is $1.75 based on the average of all estimates.
No comments:
Post a Comment